Page 84 - 南京医科大学学报自然科学版
P. 84
第43卷第6期
·826 · 南 京 医 科 大 学 学 报 2023年6月
仍然是首选 [18] ,但是,本研究可为PI⁃RADS评分4分 [8] PREISSER F,THEISSEN L,WENZEL M,et al. Perfor⁃
且 PSA>20 ng/mL 或 PI⁃RADS 评分 5 分的患者在活 mance of combined magnetic resonance imaging/ultra⁃
检方式的选择上提供一定的参考意见。 sound fusion⁃guided and systematic biopsy of the prostate
本研究存在以下不足:首先,活检病理与根治 in biopsy⁃naïve patients and patients with prior biopsies
[J]. Eur Urol Focus,2021,7(1):39-46
性术后标本的 Gleason 评分仍存在一定差异;其次,
[9] GUPTA R T,MEHTA K A,TURKBEY B,et al. PI⁃RADS:
未进行最佳靶向活检针数的确定;最后,为单中心
past,present,and future[J]. J Magn Reson Imaging,
回顾性研究,样本量相对较少,存在一定的选择偏
2020,52(1):33-53
倚,需多中心、前瞻性研究进一步验证。 [10] KASIVISVANATHAN V,RANNIKKO A S,BORGHI M,
总之,本研究结果显示,当PI⁃RADS评分4分且 et al. MRI⁃targeted or standard biopsy for prostate⁃cancer
PSA>20 ng/mL 或 PI ⁃ RADS 评 分 5 分 时 ,bpMRI ⁃ diagnosis[J]. N Engl J Med,2018,378(19):1767-1777
TRUS 结合靶向活检可在不增加 CiPCa 的基础上获 [11] EPSTEIN J I,FENG Z Y,TROCK B J,et al. Upgrading
得与靶向联合系统活检相似或不亚于其的CsPCa阳 and downgrading of prostate cancer from biopsy to radical
性率;而且与根治性术后病理结果具有高度一致性。 prostatectomy:incidence and predictive factors using the
因此,对于bpMRI上病灶明显或无法耐受多针活检、 modified gleason grading system and factoring in tertiary
grades[J]. Eur Urol,2012,61(5):1019-1024
严重术后并发症的患者,可选择单纯靶向活检。
[12] WEINREB J C,BARENTSZ J O,CHOYKE P L,et al. PI⁃
[参考文献] RADS prostate imaging ⁃ reporting and data system:
2015,version 2[J]. Eur Urol,2016,69(1):16-40
[1] PALUMBO P,MANETTA R,IZZO A,et al. Biparametric
(bp)and multiparametric(mp)magnetic resonance imag⁃ [13] SEREFOGLU E C,ALTINOVA S,UGRAS N S,et al.
ing(MRI)approach to prostate cancer disease:a narrative How reliable is 12⁃core prostate biopsy procedure in the
detection of prostate cancer?[J]. Can Urol Assoc J,2013,
review of current debate on dynamic contrast enhancement
[J]. Gland Surg,2020,9(6):2235-2247 7(5):293-298
[2] JEMAL A,SIEGEL R,XU J,et al. Cancer statistics,2010 [14] AHDOOT M,WILBUR A R,REESE S E,et al. MRI⁃tar⁃
[J]. CA A Cancer J Clin,2010,60(5):277-300 geted,systematic,and combined biopsy for prostate cancer
[3] 郑雨潇,徐浩翔,李 潇,等. 前列腺穿刺活检前预测 diagnosis[J]. N Engl J Med,2020,382(10):917-928
Gleason 评分≥7 风险模型的建立及其临床意义[J]. [15] THESTRUP K C D,LOGAGER V,BASLEV I,et al. Bipa⁃
南京医科大学学报(自然科学版),2017,37(3):340- rametric versus multiparametric MRI in the diagnosis of
prostate cancer[J/OL]. Acta Radiol Open,2016,5(8)
343
[4] STABILE A,DELL’OGLIO P,DE COBELLI F,et al. [2022⁃11⁃01]. DOI:10.1177/2058460116663046
Association between prostate imaging reporting and data [16] WOO S,SUH CH,KIM S Y,et al. Head⁃to⁃head compari⁃
system(PI⁃RADS)score for the index lesion and multifo⁃ son between biparametric and multiparametric MRI for
cal,clinically significant prostate cancer[J]. Eur Urol On⁃ the diagnosis of prostate cancer:asystematic review and
meta ⁃ analysis[J]. Am J Roentgenol,2018,211(5):
col,2018,1(1):29-36
[5] MOTTET N,BELLMUNT J,BOLLA M,et al. EAU⁃ESTRO⁃ W226-W241
SIOG guidelines on prostate cancer. Part 1:screening, [17] LENFANT L,BARRET E,ROUPRÊT M,et al. Transperi⁃
diagnosis,and local treatment with curative intent[J]. neal prostate biopsy is the new black:what are the next
Eur Urol,2017,71(4):618-629 targets?[J]. Eur Urol,2022,82(1):3-5
[6] ELDRED⁃EVANS D,NEVES JB,SIMMONS L AM,et al. [18] CHUANG R J,MARKS L S. Targeted and systematic
Added value of diffusion ⁃ weighted images and dynamic biopsy for diagnosis and management of prostate cancer
contrast enhancement in multiparametric magnetic reso⁃ [J]. Clin Oncol,2020,32(3):144-148
nance imaging for the detection of clinically significant [19] MARRA G,PLOUSSARD G,FUTTERER J,et al. Contro⁃
prostate cancer in the PICTURE trial[J]. BJU Int,2020, versies in MR targeted biopsy:alone or combined,cogni⁃
125(3):391-398 tive versus software⁃based fusion,transrectal versus trans⁃
[7] LEE A Y M,YANG X Y,LEE H J,et al. Multiparametric perineal approach?[J]. World J Urol,2019,37(2):277-
MRI⁃ultrasonography software fusion prostate biopsy:ini⁃ 287
tial results using a stereotactic robotic⁃assisted transperi⁃ [20] PHILIP J,MANIKANDAN R,JAVLÉ P,et al. Prostate
neal prostate biopsy platform comparing systematic vs tar⁃ cancer diagnosis:should patients with prostate specific
geted biopsy[J]. BJU Int,2020,126(5):568-576 antigen >10 ng/mL have stratified prostate biopsy proto⁃